U.S. Global Investors (GROW) is a small investment management company with total assets of $47.2 million and consolidated shareholders' equity of $44.2 million at December 31, 2025. Under the liquidation lens, recovery posture is positive — the company's balance sheet is dominated by liquid assets. Cash and cash equivalents total $25.2 million (100% recovery) plus $1.0 million restricted cash, trading securities at fair value of $12.9 million (applying a modest 90-95% haircut to mark-to-market holdings yields ~$12.2-12.3 million), held-to-maturity debt securities net of credit losses of $958K (near 100% given current maturity), accounts receivable of $1.1 million (90-95% recovery), and prepaid/other current assets. The corporate-investments segment holds $2.8 million in equity securities without readily determinable fair value (measurement alternative) subject to a more substantial haircut — historical cumulative downward adjustments of $5.4 million against upward adjustments of $3.9 million indicate prior impairment history; liquidation recovery on this position is genuinely uncertain. PP&E net book value of $1.1 million (50-70% recovery) and a finance lease ROU asset of $78K are minor. Intangibles and deferred tax assets ($650K) receive zero recovery under the lens. Against total liabilities of only $3.1 million at face value — comprising current liabilities of $2.0 million and noncurrent liabilities of $1.1 million (including $833K uncertain tax position reserve and $59K finance lease noncurrent) — the liquidation surplus to equity is clearly positive. A rough floor recovery: cash ~$26.2M + trading securities ~$12.3M + HTM debt ~$958K + receivables ~$1.0M + prepaid/other current ~$658K + HTM deposit ~$1.0M = ~$42.1M against total liabilities at face $3.1M yields ~$39M in recovery, ahead of MFFAIS's $23.2M CLV figure, though that figure may apply stricter haircuts to the investment portfolio. The Q2 FY2026 result was distorted by a $1.3M tax expense related to HIVE convertible securities accounting; the company has disclosed it expects an offsetting $1.3M benefit in Q3 FY2026. This tax liability does not appear to create a balance-sheet obligation that survives wind-up beyond what is already reflected in the current tax payable and deferred tax liability. No new material operating lease commitments or long-term debt were added. Shares outstanding declined from ~13.6M to ~12.9M YoY due to buybacks, modestly increasing per-share recovery. From the prior 10-Q (September 30, 2025, total assets $48.9M estimated from prior XBRL), total assets declined ~$1.7M driven by continued share repurchases ($1.1M six months), dividends ($579K), and net income of only $661K. The deferred tax asset contracted sharply from $1.86M (December 2024) to $650K (December 2025) reflecting the HIVE-related valuation allowance applied against capital loss carryforwards. Filing discusses the HIVE measurement-alternative unrealized gains ($1.3M six-month period, additional $1.9M subsequent event) in MD&A but does not separately tag the measurement-alternative asset at a gross balance-sheet level in XBRL — it rolls into EquitySecuritiesWithoutReadilyDeterminableFairValueAmount at $2.8M combined.
▼ Community Notes